Abstract

To determine the significance of P57KIP2 immunohistochemistry expression in the histopathological diagnosis of hydatidiform mole. Hydatidiform mole patients at King Chulalongkorn Memorial Hospital between January 1999 and December 2011 were recruited. Two gynecologic pathologists reviewed histopathologic slides to confirm diagnosis. Formalin-fixed, paraffin-embedded tissue sections were stained using a bstandard immunostaining system with monoclonal antibodies against P57KIP2 protein. Correlations among pathological features, immunohistochemical expression and clinical data were analyzed. One hundred and twenty-seven hydatidiform mole patients were enrolled. After consensus review, 97 cases were diagnosed as complet (CHM) and 30 cases as partial (PHM). Discordance between the first and final H and E diagnoses was found in 19 cases (14.9%, k= 0.578). Significant pathological features to classify the type of hydatidiform mole are central cisterns, trophoblastic proliferation, trophoblastic atypia, two populations of villi, fetal vessels and scalloped borders. After performing immunohistochemistry for P57KIP2, 107 cases were P57KIP2 negative and 20 cases positive. Discordant diagnoses between final H and E diagnosis and P57KIP2 immunohistochemistry was identified in 12 cases (9.4%). Sensitivity of final H and E diagnosis for CHM was 89.7%; specificity was 95.0%. PHM sensitivity and specificity of final H and E diagnosis was 95.0% and 89.7%, respectively. Histopathological diagnosis alone has certain limitations in accurately defining types of hydatidiform mole; P57KIP2 immunohistochemistry is practical and can be a useful adjunct to histopathology to distinguish CHM from non-CHM.

Highlights

  • The hydatidiform mole is a term used for a group of pregnancy-related tumors

  • 97 cases were diagnosed as complet (CHM) and 30 cases as partial (PHM)

  • Discordant diagnoses between final hematoxylin and eosin (H&E) diagnosis and P57KIP2 immunohistochemistry was identified in 12 cases (9.4%)

Read more

Summary

Introduction

The hydatidiform mole is a term used for a group of pregnancy-related tumors. The incidence varies greatly among different parts of the world with an approximate risk of 1 per 1000 pregnancies (Ngan et al, 2012). The reported incidence of hydatidiform mole is high in Asia. At King Chulalongkorn Memorial Hospital (KCMH), Bangkok, Thailand, the reported incidence is approximately 1 in 600 pregnancies (Wairachpanich et al, 2015). Majority of patients with hydatidiform mole have spontaneous regression after evacuation. In some patients, serum hCG levels rise or plateau after treatment and are considered postmolar gestational trophoblastic neoplastic neoplasia (GTN)

Objectives
Methods
Results
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call